Estimation of cost-effectiveness in randomised controlled trials when not all participants allocated to active intervention receive it by Metcalfe, Chris
POSTER PRESENTATION Open Access
Estimation of cost-effectiveness in randomised
controlled trials when not all participants
allocated to active intervention receive it
Chris Metcalfe
From Clinical Trials Methodology Conference 2011
Bristol, UK. 4-5 October 2011
Objectives
In randomised controlled trials (RCTs) with some parti-
cipants allocated to active intervention not complying
with it, intention-to-treat analyses are recognised as
underestimating the treatment effect on those partici-
pants who do comply. As compliance with treatment is
often associated with prognosis, the alternative per pro-
tocol analysis will usually give a biased estimate of the
treatment effect. Methods of unbiased estimation of the
treatment effect in compliers have been developed for
clinical outcome measures, but are not routinely
employed in the estimation of cost effectiveness. A sys-
tematic review examines the accommodation of non-
compliance in published RCT-based cost-effectiveness
analyses.
Methods
A systematic review of published RCTs is being underta-
ken, examining how patients who did not comply with
allocated treatment were incorporated in estimates of
cost-effectiveness. This abstract reports on preliminary
work, searching for “cost-effectiveness” and “cost-utility”
in the titles and abstracts of research articles published
in the BMJ during 2009 and 2010.
Results
Of 27 articles found, 11 were RCTs with a cost-effec-
tiveness analysis. It was not clear from the reports of 4/
11 trials whether any non-compliance occurred, with lit-
tle detail given on the extent of non-compliance in a
further 3 studies. In none of these seven studies was the
effect of non-compliance on estimates of cost-effective-
ness considered. Of the remaining studies, one con-
ducted an intention-to-treat analysis for the clinical
outcome but appeared to omit non-compliers from the
estimates of cost; one study calculated intention-to-treat
estimates of effect on the clinical and the cost outcomes
and an unbiased estimate of the clinical effect in com-
pliers; and one study included non-compliers in their
allocated groups for the main analysis but conducted a
sensitivity analysis of cost-effectiveness with these peo-
ple excluded. The fourth was a cluster-randomised trial,
which presented costs and clinical effects per catchment
area and costs per individual receiving the intervention.
Conclusions
Preliminary findings suggest that the majority of studies
take an intention-to-treat approach to comparing costs
between randomly allocated treatments. However, it is
unclear whether the costs of allocated or of received
treatment are contributing to these estimates. A minor-
ity of studies are conducting secondary per protocol
analyses, with no study attempting an unbiased estimate
of cost-effectiveness in compliers. How the costs of par-
tial compliance, which may be associated with treatment
success, can be incorporated into these estimates with-
out causing bias is unclear.
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